Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLCG1 | P19174 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.38 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA5A | P35218 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29280609 | 0.85 | NPSR1 (0.45) | PLCG1NPSR1KCNN4SRCPDK1 | |
| SCHEMBL31612952 | 0.85 | NPSR1 (0.45) | PLCG1NPSR1KCNN4SRCPDK1 | |
| SCHEMBL29108677 | 0.83 | PLCG1 (0.44) | PLCG1NPSR1KCNN4SRCKMT2A | |
| SCHEMBL22745946 | 0.82 | CA1 (0.44) | PLCG1NPSR1KCNN4KMT2AMEN1 | |
| SCHEMBL27801144 | 0.81 | PLCG1 (0.51) | PLCG1NPSR1KCNN4SRCELANE | |
| SCHEMBL9129412 | 0.80 | SRC (0.43) | PLCG1NPSR1KCNN4SRCKMT2A | |
| SCHEMBL4964275 | 0.79 | PLCG1 (0.50) | PLCG1NPSR1KCNN4SRCPDK1 | |
| SCHEMBL11708179 | 0.79 | TSHR (0.52) | PLCG1NPSR1KCNN4SRCHTT | |
| SCHEMBL31251995 | 0.79 | PTGDR2 (0.45) | PLCG1KCNN4KMT2AMEN1NPC1 | |
| SCHEMBL3136256 | 0.79 | KMT2A (0.41) | PDK1PDK2PDK3PDK4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115093334-B | Organic electroluminescent compound, preparation method thereof and organic electroluminescent device | 吉林奥来德光电材料股份有限公司 | 2023-04-07 | — | — | CN | claimed |
| CN-115093334-A | Organic electroluminescent compound, preparation method thereof and organic electroluminescent device | 吉林奥来德光电材料股份有限公司 | 2022-09-23 | — | — | CN | claimed |
| US-20240083857-A1 | 2-Methyl-Quinazolines | Bayer Pharma AG (DE) | 2024-03-14 | — | — | US | disclosed |
| CN-115093334-B | Organic electroluminescent compound, preparation method thereof and organic electroluminescent device | 吉林奥来德光电材料股份有限公司 | 2023-04-07 | — | — | CN | disclosed |
| CN-115093334-A | Organic electroluminescent compound, preparation method thereof and organic electroluminescent device | 吉林奥来德光电材料股份有限公司 | 2022-09-23 | — | — | CN | disclosed |
| US-20220235013-A1 | 2-METHYL-QUINAZOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-07-28 | — | — | US | disclosed |
| EP-3601267-A1 | 2-METHYL-QUINAZOLINES | Bayer Pharma Aktiengesellschaft (DE) | 2020-02-05 | — | — | EP | disclosed |
| WO-2018172250-A1 | 2-METHYL-QUINAZOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-09-27 | — | — | WO | disclosed |
| US-8623911-B2 | Boron-containing small molecules as anti-protozoal agent | ANACOR PHARMACEUTICALS, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-8623911-B2 | Boron-containing small molecules as anti-protozoal agent | ANACOR PHARMACEUTICALS, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-8623911-B2 | Boron-containing small molecules as anti-protozoal agent | ANACOR PHARMACEUTICALS, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-20130231304-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTI-PROTOZOAL AGENT | ANACOR PHARMACEUTICALS, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| CN-101628872-B | New method for preparing functionalised benzocyclobutenes and its application in the synthesis of ivabradine and its addition salts | CENTRE NAT RECH SCIENT | 2013-04-17 | — | — | CN | disclosed |
| US-8288581-B2 | Process for the preparation of functionalised benzocyclobutenes, and application in the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | LES LABORATOIRES SERVIER (FR) | 2012-10-16 | — | — | US | disclosed |
| US-20120116112-A1 | PROCESS FOR THE PREPARATION OF FUNCTIONALISED BENZOCYCLOBUTENES, AND APPLICATION IN THE SYNTHESIS OF IVABRADINE AND ADDITION SALTS THEREOF WITH A PHARMACEUTICALLY ACCEPTABLE ACID | LES LABORATOIRES SERVIER (FR) | 2012-05-10 | — | — | US | disclosed |
| US-8110701-B2 | Process for the preparation of functionalised benzocyclobutenes, and application in the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | LES LABORATOIRES SERVIER (FR) | 2012-02-07 | — | — | US | disclosed |
| WO-2011116348-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTI-PROTOZOAL AGENT | ANACOR PHARMACEUTICALS, INC. (US) | 2011-09-22 | — | — | WO | disclosed |
| WO-2011116348-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTI-PROTOZOAL AGENT | ANACOR PHARMACEUTICALS, INC. (US) | 2011-09-22 | — | — | WO | disclosed |
| US-20100016580-A1 | Process for the preparation of functionalised benzocyclobutenes, and application in the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | LES LABORATOIRES SERVIER (FR) | 2010-01-21 | — | — | US | disclosed |
| CN-101628872-A | New method for preparing functionalised benzocyclobutenes and its application to the synthesis of ivabradine and its addition salts with a pharmaceutically acceptable acid | SERVIER LAB | 2010-01-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240083857-A1 | 2-Methyl-Quinazolines | NRAS, KRAS, KSR2 | PLCG1 1958/4885NPSR1 1753/4885KCNN4 4022/4885 |
| US-20100016580-A1 | Process for the preparation of functionalised benzocyclobutenes, and application in the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | BDKRB2, HRH2, C1R | PLCG1 4112/4885NPSR1 808/4885KCNN4 116/4885 |
| US-20120116112-A1 | PROCESS FOR THE PREPARATION OF FUNCTIONALISED BENZOCYCLOBUTENES, AND APPLICATION IN THE SYNTHESIS OF IVABRADINE AND ADDITION SALTS THEREOF WITH A PHARMACEUTICALLY ACCEPTABLE ACID | CYP4F2, CYP2B6, CYP4F8 | PLCG1 4486/4885NPSR1 916/4885KCNN4 175/4885 |
| US-20220235013-A1 | 2-METHYL-QUINAZOLINES | NRAS, KRAS, KSR2 | PLCG1 1958/4885NPSR1 1753/4885KCNN4 4022/4885 |
| US-20130231304-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTI-PROTOZOAL AGENT | BRDT, BRI3BP, BTN3A1 | PLCG1 2547/4885NPSR1 3286/4885KCNN4 4201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.